XML 81 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions - Purchase price as of the Regentys acquisition (Details) - USD ($)
Jul. 31, 2020
Jul. 31, 2019
Jan. 07, 2019
Nov. 27, 2018
Jul. 31, 2018
Cash and cash equivalents $ 15,452 $ 298,485 $ 61,857   $ 1,046,365
Other current assets 332,268 275,731 13,138    
Property and equipment, net 213,668 499,993 444    
Accounts payable and accrued liabilities (23,907,718) (14,684,060) (1,181,920)    
Notes payable (10,666,703) (8,368,379) (639,009)    
Loans from related parties     (16,506)    
Deferred tax liability     (889,782)    
In-process research & development     3,510,680    
Note receivable from Generex     14,345,205    
Redeemable non-controlling interest 4,073,898 4,073,898 (4,073,898)    
Non-controlling interest 9,497,709 16,974,439 (9,870,762)    
Cash paid prior to the time of closing     0    
Total Fair Value of Assets Acquired     1,259,447    
Cash paid prior to the time of closing     400,000    
Note receivable from Generex     14,345,205    
Goodwill $ 34,489,342 $ 38,297,573 13,485,758   $ 0
Allocation Adjustments          
Cash and cash equivalents     0 $ (400,000)  
Other current assets     20,543 0  
Property and equipment, net     0    
Accounts payable and accrued liabilities     (306,951)    
Notes payable     29,685    
Loans from related parties     (399,999)    
Deferred tax liability     30,320 397,513  
In-process research & development     (119,630) (1,521,000)  
Note receivable from Generex     (2,791) 0  
Non-controlling interest     (2,791) 0  
Cash paid prior to the time of closing     400,000 400,000  
Total Fair Value of Assets Acquired     (351,614) (1,383,485)  
Cash paid prior to the time of closing     0 0  
Note receivable from Generex     (2,791) 0  
Goodwill     348,823 1,383,485  
Revised Allocation          
Cash and cash equivalents     61,857 208,419  
Other current assets     33,681 37,950  
Property and equipment, net     444    
Accounts payable and accrued liabilities     (1,488,871)    
Notes payable     (609,324)    
Loans from related parties     (416,505)    
Deferred tax liability     (859,462) (642,660)  
In-process research & development     3,391,050 2,459,000  
Note receivable from Generex     14,342,414 11,472,663  
Redeemable non-controlling interest     (4,073,898)    
Non-controlling interest     (9,873,553) (11,999,559)  
Cash paid prior to the time of closing     400,000 400,000  
Total Fair Value of Assets Acquired     907,833 2,461,440  
Cash paid prior to the time of closing     400,000 400,000  
Note receivable from Generex     14,342,414 11,472,664  
Goodwill     $ 13,834,581 $ 9,411,224